The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Monoclonal antibodies to target epidermal growth factor receptor–positive tumors: A new paradigm for cancer therapy
Open accessAbstract
BACKGROUND: Traditional cytotoxic approaches to tumor management are associated with efficacy and toxicity limitations. Blockade of the epidermal growth factor receptor (EGFR) and its ligands is a novel approach to the treatment of human tumors that offers a noncytotoxic alternative to cancer treatment. METHODS: An English‐language literature search was conducted to identify studies assessing the in vitro and in vivo effects of EGFR blockade with an emphasis on approaches that use monoclonal antibody therapy. RESULTS: The EGF pathway regulates normal cellular processes and appears to be correlated with the development of malignancy. Approximately 30% of human tumors express EGFR, which has been reported to be correlated with poor prognosis and diminished disease‐free and overall survival in selected tumor types. A number of anti‐EGFR monoclonal antibodies have been developed, which currently are undergoing clinical trials in humans. Effective anti‐EGFR monoclonal antibodies compete with endogenous ligands, primarily EGF and transforming growth factor–α, for receptor ligand‐binding sites. Binding to EGFR blocks critical signaling pathways and interferes with the growth of tumors expressing EGFR. Anti‐EGFR monoclonal antibodies that currently are under study include IMC‐C225, EMD 55900, ICR 62, and ABX‐EGF. CONCLUSIONS: These antibodies have demonstrated promising results and appear to have been well tolerated. EGFR‐targeted therapy addresses important, unmet needs in the treatment of human tumors, particularly EGFR‐positive epithelial tumors including common malignancies of the head and neck, lung, and colon. Cancer 2002;94:1593–611. © 2002 American Cancer Society. DOI 10.1002/cncr.10372
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lydon, N., Mett, H., Mueller, M. R., Becker, M. A., Cozens, R. M., Stover, D. R., Daniels, D., Traxler, P. M., & Buchdunger, E. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980330)76:1<154::aid-ijc24>3.0.co;2-b · Cited by 31
RetractedSlamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Carpenter, G., & Cohen, S. (1979) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.48.070179.001205 · Cited by 2,909
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Cited by
Cancer Cell Imaging and Photothermal Therapy in the Near-Infrared Region by Using Gold Nanorods
Huang, X., El-Sayed, I. H., Qian, W., & El-Sayed, M. A. (2006) · Journal of the American Chemical Society · doi:10.1021/ja057254a · Cited by 5,436
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags
Qian, X., Peng, X.-H., Ansari, D. O., Yin-Goen, Q., Chen, G. Z., Shin, D. M., Yang, L., Young, A. N., Wang, M. D., & Nie, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1377 · Cited by 2,201
Self-citationQuantum Dots and Their Multimodal Applications: A Review
Bera, D., Qian, L., Tseng, T.-K., & Holloway, P. H. (2010) · Materials · doi:10.3390/ma3042260 · Cited by 1,365
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012) · Science · doi:10.1126/science.1226338 · Cited by 1,322
Au nanoparticles target cancer
Jain, P. K., El-Sayed, I. H., & El-Sayed, M. A. (2007) · Nano Today · doi:10.1016/s1748-0132(07)70016-6 · Cited by 1,157
Single-molecule and single-nanoparticle SERS: from fundamental mechanisms to biomedical applications
Qian, X.-M., & Nie, S. M. (2008) · Chemical Society Reviews · doi:10.1039/b708839f · Cited by 1,105
Recent Advances in Head and Neck Cancer
Haddad, R. I., & Shin, D. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707975 · Cited by 916
Self-citationEpidermal growth factor receptor targeting in cancer: a review of trends and strategies
Yewale, C., Baradia, D., Vhora, I., Patil, S., & Misra, A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.100 · Cited by 533
Baselga, J., Trigo, J. M., Bourhis, J., Tortochaux, J., Cortés-Funes, H., Hitt, R., Gascón, P., Amellal, N., Harstrick, A., & Eckardt, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.119 · Cited by 490
Zhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482
Hong, F., Yan, J., Baran, J. T., Allendorf, D. J., Hansen, R. D., Ostroff, G. R., Xing, P. X., Cheung, N.-K. V., & Ross, G. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.797 · Cited by 472
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer
Patra, C. R., Bhattacharya, R., Mukhopadhyay, D., & Mukherjee, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.007 · Cited by 458
Epidermal growth factor receptor inhibition strategies in oncology
Harari, P. M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00600 · Cited by 423
Triple-negative breast cancer: is there a treatment on the horizon?
Yao, H., He, G., Yan, S., Chen, C., Song, L., Rosol, T. J., & Deng, X. (2017) · Oncotarget · doi:10.18632/oncotarget.12284 · Cited by 394
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Widakowich, C., de Castro, G., de Azambuja, E., Dinh, P., & Awada, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1443 · Cited by 324
Signaling through the epidermal growth factor receptor during the development of malignancy
Grandis, J. R., & Sok, J. C. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.01.002 · Cited by 320
Nanophotosensitizers toward advanced photodynamic therapy of Cancer
Lim, C.-K., Heo, J., Shin, S., Jeong, K., Seo, Y. H., Jang, W.-D., Park, C. R., Park, S. Y., Kim, S., & Kwon, I. C. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.09.012 · Cited by 293
Huang, X., Qian, W., El‐Sayed, I. H., & El‐Sayed, M. A. (2007) · Lasers in Surgery and Medicine · doi:10.1002/lsm.20577 · Cited by 290
(2003) · PubMed · Cited by 272
Rosell, R., Robinet, G., Szczesna, A., Ramlau, R., Constenla, M., Mennecier, B. C., Pfeifer, W., O’Byrne, K. J., Welte, T., Kolb, R., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm474 · Cited by 258
Santini, D., Loupakis, F., Vincenzi, B., Floriani, I., Stasi, I., Canestrari, E., Rulli, E., Maltese, P. E., Andreoni, F., Masi, G., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0181 · Cited by 234
Molecular determinants of cetuximab efficacy.
Vallböhmer, D., Zhang, W., Gordon, M., Yang, D. Y., Yun, J., Press, O. A., Rhodes, K. E., Sherrod, A. E., Iqbal, S., Danenberg, K. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.100 · Cited by 234
Metadata
- Authors
- Herbst, R. S., & Shin, D. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2002-03
- Volume
- 94
- Issue
- 5
- Pages
- 1593-1611
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2079286299
- Cited by
- 446
- References
- 105
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.